333389-44-9

Basic information

• Product Name: AcetaMide, 2-chloro-N-(3,3-diMethyl-2-oxobutyl)-
• Synonyms: AcetaMide, 2-chloro-N-(3,3-diMethyl-2-oxobutyl)-;2-Chloro-N-(3,3-dimethyl-2-oxobutyl)acetamide
• CAS NO: 333389-44-9
• Molecular Formula: C₈H₁₄ClNO₂
• Molecular Weight: 191.65526
• Mol File: 333389-44-9.mol
• Article Data: 6

Chemical Properties

• Melting Point: 50-52 °C
• Boiling Point: 328.1±27.0 °C(Predicted)
• Appearance: /
• Density: 1.094±0.06 g/cm3(Predicted)
• PKA: 12.69±0.46(Predicted)
• CAS DataBase Reference: AcetaMide, 2-chloro-N-(3,3-diMethyl-2-oxobutyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: AcetaMide, 2-chloro-N-(3,3-diMethyl-2-oxobutyl)-(333389-44-9)
• EPA Substance Registry System: AcetaMide, 2-chloro-N-(3,3-diMethyl-2-oxobutyl)-(333389-44-9)

Safety Data

• Hazardous Substances Data: 333389-44-9(Hazardous Substances Data)

Upstream product

• 13547-70-1 1-chloro-3,3-dimethyl-butan-2-one 
• 5469-26-1 1-Bromopinacolon 
• 76779-98-1 1-azido-3,3-dimethyl-2-butanone 
• 79-04-9 chloroacetyl chloride 
• 33119-72-1 1-amino-3,3-dimethylbutan-2-one hydrochloride 

Downstream Products

• 1012056-34-6 4-(4-(2-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-ylamino)-2-oxoethyl)phenoxy)-N-hydroxybutanamide 
• 1133000-85-7 3-(4-(2-(5-((5-tert-butyloxazol-2-yl)methylthio)-thiazol-2-ylamino)-2-oxoethyl)phenoxy)-N-hydroxypropanamide 
• 1133001-70-3 (E)-methyl 3-(4-(N-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-yl)-sulfamoyl)phenyl)acrylate 
• 1133001-58-7 methyl 4-(N-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-yl)sulfamoyl)benzoate 
• 1133001-45-2 (E)-methyl 3-(3-(N-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-yl)-sulfamoyl)phenyl)acrylate 
• 1133001-16-7 methyl 4-(4-(1-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-ylamino)-2-methyl-1-oxopropan-2-yl)phenoxy)butanoate 
• 1133000-87-9 methyl 3-(4-(2-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-ylamino)-2-oxoethyl)phenoxy)propanoate 
• 1133001-19-0 ethyl 4-(4-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-ylcarbamoyloxy)phenoxy)butanoate 
• 1133001-28-1 ethyl 4-(4-(3-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-yl)ureido)phenoxy)butanoate 
• 1133001-42-9 methyl 4-(4-(1-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-ylamino)-1-oxopropan-2-yl)phenoxy)butanoate 
• 1133001-82-7 methyl 4-(3-(2-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-yl-amino)-2-oxoethyl)phenoxy)butanoate 
• 1133000-56-2 (E)-ethyl 3-(4-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-yl-carbamoyl)phenyl)acrylate 
• 1012059-90-3 methyl-5-(4-(2-(5-((5-tert-butyloxazol-2-yl)methylthio)-thiazol-2-ylamino)-2-oxoethyl)phenoxy)pentanoate 
• 1012059-88-9 methyl 4-(4-(2-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-ylamino)-2-oxoethyl)phenoxy)butanoate 

Relevant articles and documents

Nitrogen Mustard Derivatives

The disclosure includes compounds of Formula (1): wherein X1, X2, Q, Z, R1, and R2 are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compounds.

CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY

The present invention relates to CDK inhibitors and their use in the treatment of cell proliferative diseases such as cancer. The compounds of the invention may further act as HDAC inhibitors.

N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases

The present invention describes compounds of formula I: and enantiomers, diastereomers and pharmaceutically acceptable salts thereof. The formula I compounds are protein kinase inhibitors and are useful in the treatment of proliferative diseases, for exam